Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, California.
California Pacific Medical Center Research Institute, San Francisco, California.
Cancer Res. 2021 Jun 1;81(11):2956-2969. doi: 10.1158/0008-5472.CAN-20-3450. Epub 2021 Mar 25.
Melanoma occurs as a consequence of inherited susceptibility to the disease and exposure to UV radiation (UVR) and is characterized by uncontrolled cellular proliferation and a high mutational load. The precise mechanisms by which UVR contributes to the development of melanoma remain poorly understood. Here we show that activation of nuclear receptor coactivator 3 (NCOA3) promotes melanomagenesis through regulation of UVR sensitivity, cell-cycle progression, and circumvention of the DNA damage response (DDR). Downregulation of NCOA3 expression, either by genetic silencing or small-molecule inhibition, significantly suppressed melanoma proliferation in melanoma cell lines and patient-derived xenografts. NCOA3 silencing suppressed expression of xeroderma pigmentosum C and increased melanoma cell sensitivity to UVR. Suppression of NCOA3 expression led to activation of DDR effectors and reduced expression of cyclin B1, resulting in G-M arrest and mitotic catastrophe. A SNP in NCOA3 (T960T) reduced NCOA3 protein expression and was associated with decreased melanoma risk, given a significantly lower prevalence in a familial melanoma cohort than in a control cohort without cancer. Overexpression of wild-type NCOA3 promoted melanocyte survival following UVR and was accompanied by increased levels of UVR-induced DNA damage, both of which were attenuated by overexpression of NCOA3 (T960T). These results describe NCOA3-regulated pathways by which melanoma can develop, with germline NCOA3 polymorphisms enabling enhanced melanocyte survival in the setting of UVR exposure, despite an increased mutational burden. They also identify NCOA3 as a novel therapeutic target for melanoma. SIGNIFICANCE: This study explores NCOA3 as a regulator of the DDR and a therapeutic target in melanoma, where activation of NCOA3 contributes to melanoma development following exposure to ultraviolet light.
黑色素瘤是由于遗传易感性和暴露于紫外线辐射(UVR)而发生的,其特征是细胞不受控制地增殖和高突变负荷。UVR 促进黑色素瘤发生的确切机制仍知之甚少。在这里,我们表明核受体共激活因子 3(NCOA3)的激活通过调节 UVR 敏感性、细胞周期进程和绕过 DNA 损伤反应(DDR)来促进黑色素瘤发生。通过遗传沉默或小分子抑制下调 NCOA3 表达,可显著抑制黑色素瘤细胞系和患者来源异种移植物中的黑色素瘤增殖。NCOA3 沉默抑制 Xeroderma Pigmentosum C 的表达并增加黑色素瘤细胞对 UVR 的敏感性。抑制 NCOA3 表达导致 DDR 效应物的激活和细胞周期蛋白 B1 的表达减少,导致 G1-M 期阻滞和有丝分裂灾难。NCOA3 中的 SNP(T960T)降低了 NCOA3 蛋白表达,并与黑色素瘤风险降低相关,因为在家族性黑色素瘤队列中的患病率明显低于无癌症的对照组。UVR 后野生型 NCOA3 的过表达促进黑素细胞存活,并伴有 UVR 诱导的 DNA 损伤水平增加,这两者均通过过表达 NCOA3(T960T)而减弱。这些结果描述了 NCOA3 调节的黑色素瘤发生途径,种系 NCOA3 多态性使黑色素细胞在暴露于 UVR 时能够增强存活,尽管突变负担增加。它们还确定 NCOA3 是黑色素瘤的一个新的治疗靶点。意义:本研究探讨了 NCOA3 作为 DDR 的调节剂和黑色素瘤的治疗靶点,其中 NCOA3 的激活有助于 UVR 暴露后黑色素瘤的发展。